I am a
Home I AM A Search Login

Papers of the Week

Papers: 8 Jul 2023 - 14 Jul 2023


Neurobiology, Pharmacology/Drug Development


2023 Jul 12

Nat Rev Neurol


The 5-HT receptor as the target of ditans in migraine – from bench to bedside.


Mitsikostas DD, Waeber C, Sanchez-Del-Rio M, Raffaelli B, Ashina H, Maassen van den Brink A, Andreou A, Pozo-Rosich P, Rapoport A, Ashina M, Moskowitz MA


Migraine is a leading cause of disability in more than one billion people worldwide, yet it remains universally underappreciated, even by individuals with the condition. Among other shortcomings, current treatments (often repurposed agents) have limited efficacy and potential adverse effects, leading to low treatment adherence. After the introduction of agents that target the calcitonin gene-related peptide pathway, another new drug class, the ditans – a group of selective serotonin 5-HT receptor agonists – has just reached the international market. Here, we review preclinical studies from the late 1990s and more recent clinical research that contributed to the development of the ditans and led to their approval for acute migraine treatment by the US Food and Drug Administration and the European Medicines Agency.